Drugs for treating Schistosoma mansoni infection.

BACKGROUND Schistosoma mansoni is a parasitic infection common in the tropics and sub-tropics. Chronic and advanced disease includes abdominal pain, diarrhoea, blood in the stool, liver cirrhosis, portal hypertension, and premature death. OBJECTIVES To evaluate the effects of antischistosomal drugs, used alone or in combination, for treating S. mansoni infection. SEARCH METHODS We searched MEDLINE, EMBASE and LILACS from inception to October 2012, with no language restrictions. We also searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2012) and mRCT. The reference lists of articles were reviewed and experts were contacted for unpublished studies. SELECTION CRITERIA Randomized controlled trials of antischistosomal drugs, used alone or in combination, versus placebo, different antischistosomal drugs, or different doses of the same antischistosomal drug for treating S. mansoni infection. DATA COLLECTION AND ANALYSIS One author extracted data and assessed eligibility and risk of bias in the included studies, which were independently checked by a second author. We combined dichotomous outcomes using risk ratio (RR) and continuous data weighted mean difference (WMD); we presented both with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach. MAIN RESULTS Fifty-two trials enrolling 10,269 participants were included. The evidence was of moderate or low quality due to the trial methods and small numbers of included participants.Praziquantel: Compared to placebo, praziquantel 40 mg/kg probably reduces parasitological treatment failure at one month post-treatment (RR 3.13, 95% CI 1.03 to 9.53, two trials, 414 participants, moderate quality evidence). Compared to this standard dose, lower doses may be inferior (30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 participants, low quality evidence; 20 mg/kg: RR 2.23, 95% CI 1.64 to 3.02, two trials, 341 participants, low quality evidence); and higher doses, up to 60 mg/kg, do not appear to show any advantage (four trials, 783 participants, moderate quality evidence).The absolute parasitological cure rate at one month with praziquantel 40 mg/kg varied substantially across studies, ranging from 52% in Senegal in 1993 to 92% in Brazil in 2006/2007. Oxamniquine: Compared to placebo, oxamniquine 40 mg/kg probably reduces parasitological treatment failure at three months (RR 8.74, 95% CI 3.74 to 20.43, two trials, 82 participants, moderate quality evidence). Lower doses than 40 mg/kg may be inferior at one month (30 mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four trials, 268 participants, low quality evidence; 20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99, two trials, 190 participants, low quality evidence), and higher doses, such as 60 mg/kg, do not show a consistent benefit (four trials, 317 participants, low quality evidence).These trials are now over 20 years old and only limited information was provided on the study designs and methods. Praziquantel versus oxamniquine: Only one small study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg and we are uncertain which treatment is more effective in reducing parasitological failure (one trial, 33 participants, very low quality evidence). A further 10 trials compared oxamniquine at 20, 30 and 60 mg/kg with praziquantel 40 mg/kg and did not show any marked differences in failure rate or percent egg reduction.Combination treatments: We are uncertain whether combining praziquantel with artesunate reduces failures compared to praziquantel alone at one month (one trial, 75 participants, very low quality evidence).Two trials also compared combinations of praziquantel and oxamniquine in different doses, but did not find statistically significant differences in failure (two trials, 87 participants). Other outcomes and analyses: In trials reporting clinical improvement evaluating lower doses (20 mg/kg and 30 mg/kg) against the standard 40 mg/kg for both praziquantel or oxamniquine, no dose effect was demonstrable in resolving abdominal pain, diarrhoea, blood in stool, hepatomegaly, and splenomegaly (follow up at one, three, six, 12, and 24 months; three trials, 655 participants).Adverse events were not well-reported but were mostly described as minor and transient.In an additional analysis of treatment failure in the treatment arm of individual studies stratified by age, failure rates with 40 mg/kg of both praziquantel and oxamniquine were higher in children. AUTHORS' CONCLUSIONS Praziquantel 40 mg/kg as the standard treatment for S. mansoni infection is consistent with the evidence. Oxamniquine, a largely discarded alternative, also appears effective.Further research will help find the optimal dosing regimen of both these drugs in children.Combination therapy, ideally with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes in the human host should be pursued as an area for future research.

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[2]  K. Polman,et al.  Schistosoma real‐time PCR as diagnostic tool for international travellers and migrants , 2012, Tropical medicine & international health : TM & IH.

[3]  Á. Cruz,et al.  The Effect of Antihelminthic Treatment on Subjects with Asthma from an Endemic Area of Schistosomiasis: A Randomized, Double-Blinded, and Placebo-Controlled Trial , 2012, Journal of parasitology research.

[4]  J. R. Stothard,et al.  Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety. , 2012, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[5]  N. B. Rodrigues,et al.  Diagnostic Accuracy and Applicability of a PCR System for the Detection of Schistosoma mansoni DNA in Human Urine Samples from an Endemic Area , 2012, PloS one.

[6]  M. Gabriela M. Gomes,et al.  Modeling the Effects of Relapse in the Transmission Dynamics of Malaria Parasites , 2011, Journal of parasitology research.

[7]  Penelope Vounatsou,et al.  Accuracy of Urine Circulating Cathodic Antigen (CCA) Test for Schistosoma mansoni Diagnosis in Different Settings of Côte d'Ivoire , 2011, PLoS neglected tropical diseases.

[8]  Q. Zhao,et al.  Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis , 2011, Parasites & Vectors.

[9]  L. Chitsulo,et al.  A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. , 2011, PLoS neglected tropical diseases.

[10]  Yuesheng Li,et al.  Diagnosis and management of schistosomiasis , 2011, BMJ : British Medical Journal.

[11]  C. King Health metrics for helminthic infections. , 2010, Advances in parasitology.

[12]  P. Mwinzi,et al.  Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. , 2010, The Lancet. Infectious diseases.

[13]  C. Donnelly,et al.  The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment , 2010, BMC infectious diseases.

[14]  Michele Tarsilla Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[15]  C. Antunes,et al.  Comparative randomised trial of high and conventional doses of praziquantel in the treatment of schistosomiasis mansoni. , 2010, Memorias do Instituto Oswaldo Cruz.

[16]  Stefanie Knopp,et al.  Comparing Diagnostic Accuracy of Kato-Katz, Koga Agar Plate, Ether-Concentration, and FLOTAC for Schistosoma mansoni and Soil-Transmitted Helminths , 2010, PLoS neglected tropical diseases.

[17]  M. Tanner,et al.  Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution , 2009, Parasitology.

[18]  I. Adam,et al.  Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan. , 2009, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[19]  L. Chitsulo,et al.  Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54·19 , 2009, Parasitology.

[20]  Y. Zhang,et al.  The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008 , 2009, Parasitology.

[21]  J. Webster,et al.  Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes , 2009, Parasitology.

[22]  P. Garner,et al.  Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review , 2009, Parasitology.

[23]  Jürg Utzinger,et al.  Diagnostic dilemmas in helminthology: what tools to use and when? , 2009, Trends in parasitology.

[24]  D. Dunne,et al.  Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial , 2009, BMC infectious diseases.

[25]  C. Barbosa,et al.  A Rationale for Schistosomiasis Control in Elementary Schools of the Rainforest Zone of Pernambuco, Brazil , 2009, PLoS neglected tropical diseases.

[26]  M. Useh,et al.  Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. , 2009, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  D. Dunne,et al.  Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial. , 2008, The Journal of infectious diseases.

[28]  Jürg Utzinger,et al.  Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis , 2008, Current opinion in infectious diseases.

[29]  P. Coelho,et al.  Clinical therapy of schistosomiasis mansoni: the Brazilian contribution. , 2008, Acta tropica.

[30]  V. Schall,et al.  The effect of the number of stool samples on the observed prevalence and the infection intensity with Schistosoma mansoni among a population in an area of low transmission. , 2008, Acta tropica.

[31]  B. Erko,et al.  Field-based evaluation of a reagent strip test for diagnosis of schistosomiasis mansoni by detecting circulating cathodic antigen (CCA) in urine in low endemic area in Ethiopia. , 2008, Parasite.

[32]  C. King,et al.  The unacknowledged impact of chronic schistosomiasis , 2008, Chronic illness.

[33]  E. Miri,et al.  Triple drug administration (TDA), with praziquantel, ivermectin and albendazole, for the prevention of three neglected tropical diseases in Nigeria , 2008, Annals of tropical medicine and parasitology.

[34]  C. King,et al.  Asymmetries of Poverty: Why Global Burden of Disease Valuations Underestimate the Burden of Neglected Tropical Diseases , 2008, PLoS neglected tropical diseases.

[35]  I. Adam,et al.  The antischistosomal efficacies of artesunate–sulfamethoxypyrazine–pyrimethamine and artemether–lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria , 2008, Annals of tropical medicine and parasitology.

[36]  Shivashankar H. Nagaraj,et al.  Transcriptional Changes in the Hookworm, Ancylostoma caninum, during the Transition from a Free-Living to a Parasitic Larva , 2008, PLoS neglected tropical diseases.

[37]  J. Utzinger,et al.  Drugs for treating urinary schistosomiasis , 2014, The Cochrane database of systematic reviews.

[38]  J. Webster,et al.  Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda , 2007, BMC medicine.

[39]  C. King Lifting the burden of schistosomiasis--defining elements of infection-associated disease and the benefits of antiparasite treatment. , 2007, The Journal of infectious diseases.

[40]  B. Erko,et al.  Field-based evaluation of a reagent strip test for diagnosis of Schistosoma mansoni by detecting circulating cathodic antigen in urine before and after chemotherapy. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[41]  M. Tanner,et al.  Artemisinins for schistosomiasis and beyond. , 2007, Current opinion in investigational drugs.

[42]  B. Cissé,et al.  Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[43]  Luc Kestens,et al.  Human schistosomiasis , 2006, The Lancet.

[44]  J. López-Abán,et al.  A new PCR-based approach for the specific amplification of DNA from different Schistosoma species applicable to human urine samples , 2006, Parasitology.

[45]  Marcel Tanner,et al.  Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. , 2006, The Lancet. Infectious diseases.

[46]  Jeffrey D Sachs,et al.  Incorporating a Rapid-Impact Package for Neglected Tropical Diseases with Programs for HIV/AIDS, Tuberculosis, and Malaria , 2006, PLoS medicine.

[47]  A. Fenwick,et al.  Efficacy of myrrh in the treatment of human Schistosomiasis mansoni. , 2005, The American journal of tropical medicine and hygiene.

[48]  C. King,et al.  Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis , 2005, The Lancet.

[49]  D. Engels,et al.  Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. , 2005, The American journal of tropical medicine and hygiene.

[50]  P. Inyang-Etoh,et al.  Efficacy of artesunate in the treatment of urinary schistosomiasis, in an endemic community in Nigeria , 2004, Annals of tropical medicine and parasitology.

[51]  J. Habbema,et al.  Determinants of health‐seeking behaviour for schistosomiasis‐related symptoms in the context of integrating schistosomiasis control within the regular health services in Ghana , 2004, Tropical medicine & international health : TM & IH.

[52]  L. Savioli,et al.  Progress in the prevention and control of schistosomiasis and soil-transmitted helminthiasis. , 2004, Parasitology international.

[53]  P. Chiodini,et al.  Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies? , 2004, Trends in parasitology.

[54]  P Vounatsou,et al.  The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm co-infections in rural Côte d'Ivoire , 2003, Parasitology.

[55]  D. Häussinger,et al.  Ultrasound in tropical and parasitic diseases , 2003, The Lancet.

[56]  H. Madsen,et al.  Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[57]  N. Kabatereine,et al.  The relationship between age, sex, egg‐count and specific antibody responses against Schistosoma mansoni antigens in a Ugandan fishing community , 2003, Tropical medicine & international health : TM & IH.

[58]  J. Richter,et al.  The impact of chemotherapy on morbidity due to schistosomiasis. , 2003, Acta tropica.

[59]  J. Habbema,et al.  Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. , 2003, Acta tropica.

[60]  M. Tanner,et al.  Combination Chemotherapy of Schistosomiasis in Laboratory Studies and Clinical Trials , 2003, Antimicrobial Agents and Chemotherapy.

[61]  P. Coelho,et al.  Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. , 2003, Bulletin of the World Health Organization.

[62]  K. Michaelsen,et al.  Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[63]  H. Friis,et al.  Effects on serum retinol of multi-micronutrient supplementation and multi-helminth chemotherapy: a randomised, controlled trial in Kenyan school children , 2002, European Journal of Clinical Nutrition.

[64]  M. Tanner,et al.  Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[65]  L. Chitsulo,et al.  The global epidemiological situation of schistosomiasis and new approaches to control and research. , 2002, Acta tropica.

[66]  J. Vercruysse,et al.  Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. , 2002, Acta tropica.

[67]  S. D. de Vlas,et al.  Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. , 2002, Trends in parasitology.

[68]  Soil-transmitted Helminthiasis Prevention and control of schistosomiasis and soil-transmitted helminthiasis : report of a WHO expert committee , 2002 .

[69]  R. Sturrock Schistosomiasis epidemiology and control: how did we get here and where should we go? , 2001, Memorias do Instituto Oswaldo Cruz.

[70]  M. Tanner,et al.  The potential of artemether for the control of schistosomiasis. , 2001, International journal for parasitology.

[71]  B. Lell,et al.  Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. , 2001, The Journal of infectious diseases.

[72]  S. le Cessie,et al.  Dynamics of egg counts and circulating antigen levels in a recent Schistosoma mansoni focus in northern Senegal , 2001, Tropical medicine & international health.

[73]  M Tanner,et al.  Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel , 2001, Parasitology.

[74]  P. van der Stuyft,et al.  The unreliability of the Kato‐Katz technique limits its usefulness for evaluating S. mansoni infections , 2001, Tropical medicine & international health : TM & IH.

[75]  P. Magnussen,et al.  The impact of a school health programme on the prevalence and morbidity of urinary schistosomiasis in Mwera Division, Pangani District, Tanzania. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[76]  C. Hatz,et al.  The use of ultrasound in schistosomiasis. , 2001, Advances in parasitology.

[77]  M. Tanner,et al.  Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection , 2000, Tropical medicine & international health : TM & IH.

[78]  L. Chitsulo,et al.  The global status of schistosomiasis and its control. , 2000, Acta tropica.

[79]  D. Clercq,et al.  What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? , 2000, Tropical medicine & international health : TM & IH.

[80]  H. Friis,et al.  The impact of iron supplementation on reinfection with intestinal helminths and Schistosoma mansoni in western Kenya. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[81]  M. Tanner,et al.  Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial , 2000, The Lancet.

[82]  J. Vercruysse,et al.  Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[83]  M Tanner,et al.  Rapid screening for Schistosoma mansoni in western Côte d'Ivoire using a simple school questionnaire. , 2000, Bulletin of the World Health Organization.

[84]  C. King,et al.  Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. , 1999, The Journal of infectious diseases.

[85]  M. Barreto,et al.  Schistosoma mansoni infection and nutritional status in schoolchildren: a randomized, double-blind trial in northeastern Brazil. , 1998, The American journal of clinical nutrition.

[86]  M. Doenhoff Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance. , 1998, Parasitology today.

[87]  P. Boisier,et al.  Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[88]  S J De Vlas,et al.  Intraspecimen fecal egg count variation in Schistosoma mansoni infection. , 1997, The American journal of tropical medicine and hygiene.

[89]  M. Niang,et al.  Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. , 1997, The Journal of infectious diseases.

[90]  A. Deelder,et al.  Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. , 1997, The American journal of tropical medicine and hygiene.

[91]  B. Merrell,et al.  Praziquantel in the treatment of Schistosoma mansoni infection: comparison of 40 and 60 mg/kg bodyweight regimens. , 1997, The American journal of tropical medicine and hygiene.

[92]  J. Habbema,et al.  Validation of a chart to estimate true Schistosoma mansoni prevalences from simple egg counts , 1997, Parasitology.

[93]  K. Michaelsen,et al.  The impact of zinc supplementation on growth and body composition: A randomized, controlled trial among rural Zimbabwean schoolchildren , 1997, European Journal of Clinical Nutrition.

[94]  W. Jaoko,et al.  Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. , 1996, East African medical journal.

[95]  E. Odongo-Aginya,et al.  Integrated control trial of schistosomiasis at Nakiwogo fishing village near Entebbe, Uganda. , 1996, East African medical journal.

[96]  D. Engels,et al.  Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications. , 1996, The American journal of tropical medicine and hygiene.

[97]  S. D. de Vlas,et al.  Worm burdens in schistosome infections. , 1996, Parasitology today.

[98]  D. Cioli,et al.  Antischistosomal drugs: past, present ... and future? , 1995, Pharmacology & therapeutics.

[99]  J. Bennett,et al.  Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. , 1995, Pharmacological research.

[100]  M. Abdel-Bary,et al.  Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. , 1994, The American journal of tropical medicine and hygiene.

[101]  N. El-Masry,et al.  Monitoring the efficacy of different doses of praziquantel by quantification of circulating antigens in serum and urine of schistosomiasis patients , 1994, Parasitology.

[102]  T. Sukwa A community-based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. , 1993, Annals of tropical medicine and parasitology.

[103]  H. Gharbi,et al.  The use of diagnostic ultrasound in schistosomiasis attempts at standardization of methodology meeting of ultrasonography in schistosomiasis cairo egypt october 1 4 1990 , 1992 .

[104]  R. Braun-Munzinger,et al.  Repeatability and reproducibility of egg counts of Schistosoma haematobium in urine. , 1992, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[105]  S. D. de Vlas,et al.  Underestimation of Schistosoma mansoni prevalences. , 1992, Parasitology today.

[106]  D. Engels,et al.  Experiences with the control of schistosomiasis mansoni in two foci in central Africa. , 1992, Memorias do Instituto Oswaldo Cruz.

[107]  A. Massoud,et al.  Study of some aspects of cell mediated immune response in bilharzial children on a field level. , 1991, Journal of the Egyptian Society of Parasitology.

[108]  C. Kaiser,et al.  Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity seven months after treatment with praziquantel. , 1991, The American journal of tropical medicine and hygiene.

[109]  A. Deelder,et al.  Mixed Schistosoma haematobium and S. mansoni infection: effect of different treatments on the serum level of circulating anodic antigen (CAA). , 1990, Acta tropica.

[110]  J. Ehrich,et al.  Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: evaluation of morbidity. , 1990, The American journal of tropical medicine and hygiene.

[111]  H. Abu-Aisha,et al.  Praziquantel, Oxamniquine, and Metrifonate in the Treatment of Schistosomiasis in Riyadh , 1990 .

[112]  M. Tanner,et al.  Measurement of schistosomiasis-related morbidity at community level in areas of different endemicity. , 1990, Bulletin of the World Health Organization.

[113]  S. Sulaiman,et al.  TOLERANCE OF TWO BRANDS OF PRAZIQUANTEL , 1989, The Lancet.

[114]  B. Gryseels,et al.  Two-year follow-up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[115]  Abdel-Hameed Aa,et al.  A field evaluation of three dose levels of oxamniquine in Gezira--Sudan. , 1988 .

[116]  Abdel-Hameed Aa,et al.  Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. , 1988 .

[117]  Z. Zein,et al.  Comparison between the efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infections on a sugar estate in Ethiopia. , 1988, Annals of tropical medicine and parasitology.

[118]  H. Murare,et al.  Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium. , 1988, The Journal of tropical medicine and hygiene.

[119]  B. Gryseels,et al.  Cure rates and egg reduction in treatment of intestinal schistosomiasis with oxamniquine and praziquantel in Maniema, Zaire. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[120]  T. Nash,et al.  Diagnosis of pathologically confirmed Symmers' periportal fibrosis by ultrasonography: a prospective blinded study. , 1988, The American journal of tropical medicine and hygiene.

[121]  J. R. Cançado,et al.  Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique. , 1987, Revista do Instituto de Medicina Tropical de Sao Paulo.

[122]  J. Queiroz,et al.  Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil. , 1987, Revista do Instituto de Medicina Tropical de Sao Paulo.

[123]  M. Coosemans,et al.  Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[124]  R. Foster A review of clinical experience with oxamniquine. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[125]  A. D. da Cunha,et al.  Double-blind therapeutical evaluation based on the quantitative oogram technique, comparing praziquantel and oxamniquine in human schistosomiasis mansoni. , 1986, Revista do Instituto de Medicina Tropical de Sao Paulo.

[126]  J. D. de Alencar,et al.  Detection and quantification of circulating antigen in schistosomiasis by monoclonal antibody. II. The quantification of circulating antigens in human schistosomiasis mansoni and haematobium: relationship to intensity of infection and disease status. , 1986, Clinical and experimental immunology.

[127]  A. Creasey,et al.  Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren. , 1986, The Central African journal of medicine.

[128]  C. Fletcher,et al.  Schistosoma mansoni: chemotherapy of infections of different ages. , 1986, Experimental parasitology.

[129]  J. M. Zeitune,et al.  Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine. , 1986, Revista do Instituto de Medicina Tropical de Sao Paulo.

[130]  T. Ayele Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. , 1986, East African medical journal.

[131]  E. Doehring,et al.  The effect of metrifonate in mixed Schistosoma haematobium and Schistosoma mansoni infections in humans. , 1986, The American journal of tropical medicine and hygiene.

[132]  G. L. D. Rezende Survey on the clinical trial results achieved in Brazil comparing praziquantel and oxamniquine in the treatment of mansoni schistosomiasis. , 1985 .

[133]  J. Ehrich,et al.  Proteinuria, hematuria, and leukocyturia in children with mixed urinary and intestinal schistosomiasis. , 1985, Kidney international.

[134]  A. Daffalla,et al.  Relationship between intensity of infection and immunomodulation in human schistosomiasis. II. NK cell activity and in vitro lymphocyte proliferation. , 1985, Clinical and experimental immunology.

[135]  A. Fenwick,et al.  Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haematobium infections in Gezira, Sudan. , 1985, The Journal of tropical medicine and hygiene.

[136]  J. Rugemalila,et al.  Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. , 1984, The Journal of tropical medicine and hygiene.

[137]  T. Ayele Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. , 1984, East African medical journal.

[138]  Gupta Kk Schistosoma mansoni treatment with oral oxamniquine in Zambia. , 1984 .

[139]  L. Chitsulo,et al.  Oxamniquine dosage in Malawi. , 1984, East African medical journal.

[140]  A. Fenwick,et al.  A field trial using praziquantel (BiltricideR) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan. , 1983, Annals of tropical medicine and parasitology.

[141]  Branchini Ml,et al.  Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. , 1982 .

[142]  N. Katz,et al.  Double-blind clinical trial comparing praziquantel with oxamniquine in schistosomiasis mansoni. , 1982, Revista do Instituto de Medicina Tropical de Sao Paulo.

[143]  J. Lambertucci,et al.  A double blind trial with oxamniquine in chronic schistosomiasis mansoni. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[144]  N. Katz,et al.  Clinical trials with praziquantel in schistosomiasis mansoni. , 1981, Revista do Instituto de Medicina Tropical de Sao Paulo.

[145]  Omer Ah Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. , 1981 .

[146]  A. Ibrahim Evaluation of oxamniquine in the treatment of S. mansoni infection among Sudanese patients. , 1980, East African medical journal.

[147]  J. Coura,et al.  Field experiences with oral oxamniquine in the treatment of schistosomiasis mansoni. , 1980, Revista do Instituto de Medicina Tropical de Sao Paulo.

[148]  Shafei Az A preliminary report on the treatment of intestinal schistosomiasis with oxamniquine. , 1979 .

[149]  N. Katz,et al.  Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. , 1979, Bulletin of the World Health Organization.

[150]  A. H. Omer Oxamniquine for treating Schistosoma mansoni infection in Sudan. , 1978, British medical journal.

[151]  M. Lewis,et al.  Oxamniquine in the treatment of various schistosome infections in South Africa. , 1978, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[152]  M. C. Weber,et al.  Dose-finding trials of oral oxamniquine in Rhodesia. , 1976, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[153]  M. Amin,et al.  A simple thick-smear technique for the diagnosis of Schistosoma mansoni infection. , 1976, Bulletin of the World Health Organization.

[154]  N Katz,et al.  A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. , 1972, Revista do Instituto de Medicina Tropical de Sao Paulo.

[155]  M. Ka Pharmacological aspects of gastric secretion. , 1948 .

[156]  L. Hackett Spleen Measurement in Malaria. , 1944 .